Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
Completed
- Conditions
- Immune Thrombocytopenic Purpura
- Registration Number
- NCT01672151
- Lead Sponsor
- First Affiliated Hospital of Suzhou Medical College
- Brief Summary
The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.
- Detailed Description
Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
- Clinical diagnoses of idiopathic thrombocytopenic purpura
- Hormone and immune suppression, splenectomy is invalid
Exclusion Criteria
- patients had a bad tolerance to rapamycin
- platelet counts < 10*10E9/L during the treatment of rapamycin
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Jiangsu Institute of Hematology
🇨🇳Suzhou, Jiangsu, China